Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Current Leases (2024 - 2025)

Historic Current Leases for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $2.7 million.

  • Prelude Therapeutics' Current Leases rose 1530.66% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 1530.66%. This contributed to the annual value of $2.5 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Prelude Therapeutics' Current Leases stood at $2.7 million, which was up 1530.66% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Prelude Therapeutics' Current Leases ranged from a high of $2.7 million in Q3 2025 and a low of $2.2 million during Q1 2024